Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation

References

• Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498.
   PubMed Web of Science ®Google Scholar
• Working group set up by the Finnish Medical Society Duodecim and the Finnish Cardiac Society. Atrial fibrillation. Current care guidelines. Helsinki: The Finnish Medical Society Duodecim; 2017. (referred February 5, 2021). Available from: www.kaypahoito.fi. Accessed March 16, 2021.
   Google Scholar
• Granger C, Alexander J, McMurray J, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa1107039
   PubMed Web of Science ®Google Scholar
• Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi:10.1056/NEJMoa1310907
   PubMed Web of Science ®Google Scholar
• Van Ganse E, Danchin N, Mahé I, et al. Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation: the NAXOS Study. Stroke. 2020;51(7):2066–2075. doi:10.1161/STROKEAHA.120.028825
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944. doi:10.1161/STROKEAHA.118.020232
   PubMed Web of Science ®Google Scholar
• Graham DJ, Baro E, Zhang R, et al. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.e11. doi:10.1016/j.amjmed.2018.12.023
   PubMed Web of Science ®Google Scholar
• Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35(28):1897–1906. doi:10.1093/eurheartj/ehu006
   PubMed Web of Science ®Google Scholar
• Lip GY, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36(2):192–210.e20. doi:10.1016/j.clinthera.2013.12.011
   PubMed Web of Science ®Google Scholar
• Wouters H, Thijs V, Annemans L. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ. 2013;16(3):407–414. doi:10.3111/13696998.2013.766200
   PubMedGoogle Scholar
• Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98(7):573–578. doi:10.1136/heartjnl-2011-300646
   PubMed Web of Science ®Google Scholar
• Mensch A, Stock S, Stollenwerk B, Müller D. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics. 2015;33(3):271–283. doi:10.1007/s40273-014-0236-9
   PubMed Web of Science ®Google Scholar
• Kleintjens J, Li X, Simoens S, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics. 2013;31(10):909–918. doi:10.1007/s40273-013-0087-9
   PubMed Web of Science ®Google Scholar
• Rognoni C, Marchetti M, Quaglini S, Liberato NL. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis. 2015;39(2):149–154. doi:10.1007/s11239-014-1104-3
   PubMed Web of Science ®Google Scholar
• Hallinen T, Soini E, Tuovinen M. Dabigatraanin kustannusvaikuttavuus eteisvärinäpotilaiden aivohalvausten ehkäisyssä [Cost-effectiveness of dabigatran compared to warfarin in the prevention of stroke and systemic embolism in Finnish AF patients]. DOSIS. 2012;28(2):130–144. Finnish.
   Google Scholar
• Hallinen T, Soini EJ, Linna M, Saarni SI. Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients. Springerplus. 2016;5(1):1354. doi:10.1186/s40064-016-3024-5
   Google Scholar
• Hellman T, Salo H, Kulathinal S, Eloranta P, Airaksinen J, Laine J. Oraalisten antikoagulanttien käyttö eteisvärinäpotilailla vuosina 2015–2017-rekisteritutkimus [Use of oral anticoagulants among patients with atrial fibrillation in 2015–2017 – a register study]. Suom Laakaril. 2020;75(47):2531–2535. Finnish.
   Google Scholar
• Guelker JE, Ilousis D, Kröger K, Santosa F, Kowall B, Stang A. Increasing use of anticoagulants in Germany and its impact on hospitalization for gastrointestinal bleeding. Thromb Res. 2019;181:135–140. doi:10.1016/j.thromres.2019.07.009
   PubMed Web of Science ®Google Scholar
• Kelasto statistical database [homepage on the Internet]. Reimbursements of medicine expenses: number of recipients and prescription data. The Social Insurance Institution of Finland, 2021. Available from: https://www.kela.fi/kelasto. Accessed May 28, 2021.
   Google Scholar
• López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058. doi:10.1136/bmj.j5058
   PubMed Web of Science ®Google Scholar
• Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676–1681. doi:10.1161/STROKEAHA.111.000402
   PubMed Web of Science ®Google Scholar
• Thom HHZ, Hollingworth W, Sofat R, et al. Directly acting oral anticoagulants for the prevention of stroke in atrial fibrillation in England and Wales: cost-effectiveness model and value of information analysis. MDM Policy Pract. 2019;4(2):2381468319866828.
   Google Scholar
• Wisløff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics. 2014;32(6):601–612. doi:10.1007/s40273-014-0152-z
   PubMed Web of Science ®Google Scholar
• de Jong LA, Groeneveld J, Stevanovic J, et al. Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PLoS One. 2019;14(9):e0222658. doi:10.1371/journal.pone.0222658
   PubMed Web of Science ®Google Scholar
• Rannanheimo P, Hyvärinen A, Kiviniemi V. Atetsolitsumabi yhdessä nab-paklitakselin kanssa kolmoisnegatiivisen rintasyövän hoidossa [Atezolizumab in combination with nab-paclitaxel in the treatment of triple-negative breast cancer]. Finnish Medicines Agency Fimea. Fimea kehittää, arvioi ja informoi -julkaisusarja 9/2019. ISBN 978-952-7299-07-4. Finnish.
   Google Scholar
• Wikman E, Rannanheimo P Isatuksimabi yhdessä pomalidomidin ja deksametasonin kanssa uusiutuneen multippelin myelooman hoidossa [Isatuximab together with pomalidomide and dexamethasone in the treatment of relapsed multiple myeloma]. Finnish Medicines Agency Fimea. Fimea kehittää, arvioi ja informoi -julkaisusarja 3/2020. ISBN 978-952-7299-10-4. Finnish.
   Google Scholar
• Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordström D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015;10(3):e0119683. doi:10.1371/journal.pone.0119683
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Process and methods [PMG9]; 2013. Available from: https://www.nice.org.uk/article/PMG9/chapter/Foreword. Accessed May 20, 2021.
   Google Scholar
• Linna M, Keto J, Piuhola J, Vesalainen R, Hällberg V, Laine J. Eteisvärinäpotilaan sosiaali- ja terveydenhuoltopalvelujen käyttö komplikaation jälkeen [Use of social and health care services by patients with complications of atrial fibrillation]. Suom Laakaril. 2017;35:1856–1862. Finnish.
   Google Scholar
• Penttilä T, Lehto M, Niiranen J, et al. Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):29–36. doi:10.1093/ehjcvp/pvy026
   Web of Science ®Google Scholar
• Raatikainen MJP, Penttilä T, Korhonen P, Mehtälä J, Lassila R, Lehto M. The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF registry. Eur Heart J Cardiovasc Pharmacother. 2018;4(4):211–219. doi:10.1093/ehjcvp/pvy009
   Web of Science ®Google Scholar
• Lip GY, Mitchell SA, Liu X, et al. Relative efficacy and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016;204:88–94. doi:10.1016/j.ijcard.2015.11.084
   PubMed Web of Science ®Google Scholar
• Kapiainen S, Väisänen A, Haula T. Terveyden- ja sosiaalihuollon yksikkökustannuksen Suomessa vuonna 2011 [Health and social care unit costs in Finland in 2011]. THL Raportti 3/2014. Juvenes Print, Suomen Yliopistopaino Oy. Tampere. Finnish.
   Google Scholar
• T12 laboratoriotoimialue hinnasto [Tariffs for the laboratory division]. Turku: Hospital District of Southwest Finland; 2021. Finnish.
   Google Scholar
• Official public tariff of reimbursable authorized medicinal products in Finland [homepage on the Internet]. Helsinki: Pharmaceuticals Pricing Board; 2021. Available from: https://www.hila.fi/luettelot/korvattavat-myyntiluvalliset-laakevalmisteet/. Accessed February 10, 2021.
   Google Scholar
• Official Statistics of Finland (OSF). Price index of public expenditure [e-publication]. Helsinki: statistics Finland. Available from: http://www.stat.fi/til/jmhi/index_en.html. Accessed November 9, 2020.
   Google Scholar
• Lassila R. Suorat oraaliset antikoagulantit [Direct oral anticoagulants]. Lääkärin käsikirja; [updated January 8, 2021]. Available from: https://www.terveysportti.fi/apps/ltk/article/ykt01922/search/suorat%20oraaliset%20antikoagulantit. Accessed April 8, 2021. Finnish.
   Google Scholar
• Lääkkeiden hintalautakunta. Preparing a health economic evaluation to be attached to the application for reimbursement status and wholesale price for a medicinal product. Application instructions, health economic evaluation; December 17, 2019. Available from: https://www.hila.fi/content/uploads/2020/01/Instructions_TTS_2019.pdf. Accessed March 16, 2021.
   Google Scholar
• Lehto M, Niiranen J, Korhonen P, et al. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF registry. Pharmacoepidemiol Drug Saf. 2017;26(6):657–665. doi:10.1002/pds.4194
   Web of Science ®Google Scholar
• Hallinen T, Soini E. The impact of the pharmaceutical pricing system on cost-effectiveness results: finnish analysis. Open Pharmacoeconomics Health Econ J. 2011;3:6–10. doi:10.2174/1876824501103010006
   Google Scholar
• Official Statistics of Finland (OSF): Deaths [e-publication]. ISSN=1798-2545. Helsinki: statistics Finland; referred 26 May 2021. Available from: http://www.stat.fi/til/kuol/meta_en.html. Accessed May 20, 2021.
   Google Scholar
• Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–952. doi:10.1161/01.CIR.98.10.946
   PubMed Web of Science ®Google Scholar
• Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010–2017. Pharmacotherapy. 2018;38(9):907–920. doi:10.1002/phar.2158
   PubMed Web of Science ®Google Scholar
• Gurusamy VK, Brobert G, Vora P, Friberg L. Sociodemographic factors and choice of oral anticoagulant in patients with non-valvular atrial fibrillation in Sweden: a population-based cross-sectional study using data from national registers. BMC Cardiovasc Disord. 2019;19(1):43. doi:10.1186/s12872-019-1029-z
   PubMed Web of Science ®Google Scholar
• Leminen A, Pyykönen M, Tynkkynen J, Tykkyläinen M, Laatikainen T. Modeling patients’ time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants. BMC Health Serv Res. 2019;19(1):901. doi:10.1186/s12913-019-4711-z
   PubMed Web of Science ®Google Scholar